Nothing Special   »   [go: up one dir, main page]

MXPA05007466A - Metodos para el tratamiento de enfermedades pulmonares. - Google Patents

Metodos para el tratamiento de enfermedades pulmonares.

Info

Publication number
MXPA05007466A
MXPA05007466A MXPA05007466A MXPA05007466A MXPA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A MX PA05007466 A MXPA05007466 A MX PA05007466A
Authority
MX
Mexico
Prior art keywords
methods
lung diseases
treating lung
ligand
oropharyngeal
Prior art date
Application number
MXPA05007466A
Other languages
English (en)
Inventor
Daniel R Henderson
Original Assignee
Arizeke Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arizeke Pharmaceuticals Inc filed Critical Arizeke Pharmaceuticals Inc
Publication of MXPA05007466A publication Critical patent/MXPA05007466A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion describe composiciones y metodos para el tratamiento de enfermedades pulmonares. En las modalidades preferidas, los metodos involucran la administracion al sujeto via una ruta pulmonar, orofaringea o nasofaringea, de un compuesto o composicion que contiene un agente terapeutico y un elemento objetivo dirigido a un ligando. El ligando es preferiblemente un epitope en el receptor pIgR.
MXPA05007466A 2003-01-09 2004-01-09 Metodos para el tratamiento de enfermedades pulmonares. MXPA05007466A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US43937303P 2003-01-09 2003-01-09
US48004703P 2003-06-20 2003-06-20
US49484103P 2003-08-12 2003-08-12
PCT/US2004/000445 WO2004062603A2 (en) 2003-01-09 2004-01-09 Methods of treating lung diseases

Publications (1)

Publication Number Publication Date
MXPA05007466A true MXPA05007466A (es) 2006-03-08

Family

ID=32719208

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007466A MXPA05007466A (es) 2003-01-09 2004-01-09 Metodos para el tratamiento de enfermedades pulmonares.

Country Status (8)

Country Link
US (1) US20050036951A1 (es)
EP (1) EP1589943A2 (es)
KR (1) KR20050114211A (es)
AU (1) AU2004204764A1 (es)
CA (1) CA2512672A1 (es)
IL (1) IL169602A0 (es)
MX (1) MXPA05007466A (es)
WO (1) WO2004062603A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272106A1 (en) * 2004-02-17 2005-12-08 Norman Moore Methods and kits for detection of multiple pathogens
WO2006060051A2 (en) * 2004-09-13 2006-06-08 Arizeke Pharmaceuticals, Inc. Enzyme chimeras and methods of their use for the treatment of infection by bacillus anthracis
US7838532B2 (en) * 2005-05-18 2010-11-23 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US8546423B2 (en) * 2005-05-18 2013-10-01 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
US7875427B2 (en) * 2005-09-30 2011-01-25 Centocor, Inc. Compositions and methods for IL-13 biomarkers
US8795668B2 (en) * 2005-12-23 2014-08-05 The Regents Of The University Of Michigan Methods for treating pulmonary fibrosis
CA2652599C (en) * 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
AU2007259329A1 (en) * 2006-05-12 2007-12-21 Farris, Darise Anthrax compositions and methods of use and production
US20080107723A1 (en) * 2006-09-28 2008-05-08 Perkins Walter R Methods of Treating Pulmonary Distress
WO2008074868A1 (en) * 2006-12-20 2008-06-26 Ablynx N.V. Oral delivery of polypeptides
WO2008124086A2 (en) 2007-04-05 2008-10-16 President And Fellows Of Harvard College Chimeric activators: quantitatively designed protein therapeutics and uses thereof
WO2009134489A2 (en) * 2008-02-01 2009-11-05 Albany Medical College Blockage of interferon-gamma for prevention of polymicrobial synergy
US8629139B2 (en) 2008-10-07 2014-01-14 Mpex Pharmaceuticals, Inc. Topical use of Levofloxacin for reducing lung inflammation
NZ592717A (en) 2008-10-07 2013-03-28 Mpex Pharmaceuticals Inc Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation
PT2473170T (pt) 2009-09-04 2019-08-23 Horizon Orphan Llc Utilização de levofloxacina em aerossol para tratamento de fibrose cística
KR20150018765A (ko) * 2012-01-20 2015-02-24 데니스 브라운 다형교모세포종 및 수모세포종을 비롯한 신생종양 질환 및 암 줄기세포의 치료를 위한 디안히드로갈락티톨 및 유사체를 비롯한 치환된 헥시톨의 용도
KR20190134832A (ko) * 2012-03-29 2019-12-04 알토 바이오사이언스 코포레이션 종양 형성 치료방법
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
EP2906570A4 (en) * 2012-10-15 2016-06-08 Yeda Res & Dev USE OF LONG-TERM SPHINGOID BASES AND THEIR ANALOGUE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTIONS
US20160279209A1 (en) * 2013-11-04 2016-09-29 Board Of Regents, The University Of Texas System Compositions and methods for administration of an enzyme to a subject's airway
CN114671954A (zh) 2014-01-10 2022-06-28 博笛生物科技有限公司 靶向her2阳性肿瘤的化合物和组合物
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN107074958A (zh) 2014-07-09 2017-08-18 博笛生物科技有限公司 用于治疗肿瘤的抗‑pd‑l1组合
CN105440135A (zh) 2014-09-01 2016-03-30 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
CN115350279A (zh) 2016-01-07 2022-11-18 博笛生物科技有限公司 用于治疗肿瘤的抗-her2组合
CN106943597A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-egfr组合
CN115554406A (zh) 2016-01-07 2023-01-03 博笛生物科技有限公司 用于治疗肿瘤的抗-cd20组合
EP3431096B1 (en) * 2016-03-16 2024-12-18 Xie, Yanhui Glucocorticoid combined with polyethylene glycol-modified interleukin-2 for treating respiratory disease
CN118515666A (zh) 2017-04-27 2024-08-20 博笛生物科技有限公司 2-氨基-喹啉衍生物
JP7080501B2 (ja) 2017-06-23 2022-06-06 バーディー バイオファーマシューティカルズ インコーポレイテッド 医薬品組成物
IL260690A (en) 2018-07-19 2018-12-31 Yeda Res & Dev Sphingosine derivatives and their use against pulmonary bacterial infections
AU2020357866A1 (en) * 2019-10-04 2022-04-21 Rutgers, The State University Of New Jersey Targeted pulmonary delivery compositions and methods using same
CN113546172A (zh) * 2020-04-24 2021-10-26 山东大学齐鲁医院 Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用
GB202105277D0 (en) * 2021-04-13 2021-05-26 Imperial College Innovations Ltd Signal peptides

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
IL151972A0 (en) * 2000-03-27 2003-04-10 Univ California Ligands directed to the non-secretory component, non-stalk region of pigr and methods of use thereof
WO2002074787A2 (en) * 2001-02-02 2002-09-26 Arizeke Pharmaceuticals, Inc. Compositions and methods for identifying, characterizing, optimizing and using ligands to transcytotic molecules

Also Published As

Publication number Publication date
AU2004204764A1 (en) 2004-07-29
US20050036951A1 (en) 2005-02-17
EP1589943A2 (en) 2005-11-02
WO2004062603A2 (en) 2004-07-29
CA2512672A1 (en) 2004-07-29
IL169602A0 (en) 2007-07-04
KR20050114211A (ko) 2005-12-05
WO2004062603A3 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
MXPA05007466A (es) Metodos para el tratamiento de enfermedades pulmonares.
IL228069A0 (en) Antibodies specific to fcyriib and methods of using them
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
WO2006059108A3 (en) ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP0923376A4 (en) TREATMENT OF ASTHMA AND RESPIRATORY DISEASES
IL181473A0 (en) Humanized anti-beta 7 antagonists and uses therefor
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
TR200201057T2 (tr) P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları.
SE0203713D0 (sv) Novel compounds
BR0309117A (pt) Kit de inalação compreendendo pó inalável de tiotropium
MXPA04000793A (es) Novedoso metodo terapeutico.
TW200407305A (en) Novel compounds
WO2005115406A3 (en) 8-(2-hydroxyphenoxy)octyldiethanolamine and salts thereof for delivery of active agents
NO20063193L (no) Fusjonerte pyrrolokarbazoler og fremgangsmater for fremstilling derav
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
PL373841A1 (en) Biphasic composition induced by polydextrose
CY1110369T1 (el) Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη
MXPA03011702A (es) Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias.
SE9900833D0 (sv) Novel combination
SE0200657D0 (sv) Novel Formulation
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
CY1110368T1 (el) Συνεργιστικος συνδυασμος ο οποιος περιλαμβανει ροφλουμιλαστη και (r,r)-φορμοτερολη

Legal Events

Date Code Title Description
FA Abandonment or withdrawal